What did Morgan Stanley change on March 18, 2026 for JNJ?

Morgan Stanley maintained an **Overweight** rating on March 18, 2026 and cited an "expected positive" Ico approval. The firm did not issue a new price target in the published note.

How should investors read a maintained Overweight in the JNJ analyst rating?

A maintained Overweight signals continued analyst confidence relative to peers. It confirms preference but is not a new upward revision without a fresh price target.

Did Morgan Stanley provide a JNJ price target with the note?

No. Morgan Stanley did not publish a new **JNJ price target** in the March 18, 2026 note. Investors should wait for formal updates for valuation changes.

How does Meyka view this JNJ analyst rating action?

Meyka AI sees the maintained Overweight as consistent with consensus and assigns JNJ a **B+** grade. The grade factors in benchmarks, sector, growth, metrics, and analyst views.

Analyst Ratings

Morgan Stanley Maintains Overweight on Johnson & Johnson (JNJ) March 18, 2026

ByDanny Kontos March 19, 2026March 19, 2026

JNJ analyst rating: Morgan Stanley maintained an Overweight rating on Johnson & Johnson (JNJ) on March 18, 2026. The firm cited an “expected positive” Ico approval as a reason to keep confidence in JNJ’s pipeline and commercial runway. Morgan Stanley did not list a new price target in its note. The market showed minimal reaction, with a reported move of -0.17% (-$0.41) at the time of the bulletin. This item is part of Meyka AI’s real-time coverage and analyst tracking.